1. Lymphocyte Recovery Is a Major Determinant of Outcome after Matched Unrelated Myeloablative Transplantation for Myelogenous Malignancies 
Katarina Le Blanc, A. John Barrett, Marie Schaffer, PhD, Hans Hägglund, Per Ljungman, Olle Ringdén, Mats Remberger 
Biology of Blood and Marrow Transplantation 
Volume 15, Issue 9, Pages (September 2009)
DOI: /j.bbmt
Copyright © 2009 Elsevier Inc. Terms and Conditions

2. Figure 1
Distribution of absolute lymphocyte counts at day 30 after unrelated donor HSCT. Figures are given as ×109/L.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2009 Elsevier Inc. Terms and Conditions

3. Figure 2
(a) Cumulative incidence of treatment-related mortality (TRM), (b) Actuarial relapse free survival (RFS) for all patients, (c) Cumulative incidence of aGVHD grades II-IV of patients with an absolute lymphocyte count on day +30 (LC30) <0.2×109 (solid line), ×109 (dotted line) and ≥1.0×109 (dashed line). (d) Actuarial RFS for 77 patients who did not develop aGvHD before day 30.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2009 Elsevier Inc. Terms and Conditions